Sally A Frautschy

List of Publications by Year
in descending order

75	16,040	46	67
papers	citations	h-index	g-index
		50244	98753

88	88	88	19405
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A novel process driving Alzheimer's disease validated in a mouse model: Therapeutic potential. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, e12274.	1.8	8
2	Editorial: Oxidative Stress in Myocardial and Neural Remodeling. Frontiers in Physiology, 2021, 12, 606484.	1.3	0
3	The Novel Omega-6 Fatty Acid Docosapentaenoic Acid Positively Modulates Brain Innate Immune Response for Resolving Neuroinflammation at Early and Late Stages of Humanized APOE-Based Alzheimer's Disease Models. Frontiers in Immunology, 2020, 11, 558036.	2.2	14
4	A sensitive LC-MS assay using derivatization with boron trifluoride to quantify curcuminoids in biological samples. Analytical Biochemistry, 2020, 596, 113636.	1.1	6
5	A Novel Model of Mixed Vascular Dementia Incorporating Hypertension in a Rat Model of Alzheimerâ€™s Disease. Frontiers in Physiology, 2019, 10, 1269.	1.3	22
6	Curcumin restores innate immune Alzheimer's disease risk gene expression to ameliorate Alzheimer pathogenesis. Neurobiology of Disease, 2019, 127, 432-448.	2.1	70
7	Neuronal pentraxin 1: A synaptic-derived plasma biomarker in Alzheimer's disease. Neurobiology of Disease, 2018, 114, 120-128.	2.1	25
8	Curcumin Ameliorates Neuroinflammation, Neurodegeneration, and Memory Deficits in p25 Transgenic Mouse Model that Bears Hallmarks of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 60, 1429-1442.	1.2	71
9	[P3â€"124]: DIETARY LINOLEIC ACID DIFFERENTIALLY INFLUENCES BRAIN FADS ACTIVITIES INCREASING AN Nâ€6 METABOLITE THAT INHIBITS INFLAMMATION AND PROMOTES AMYLOIDâ€Î² CLEARANCE. Alzheimer's and Dementia, 2017, 13, P982.	0.4	3
10	P3â€147: APOE4â€Dependent Synapticâ€Derived Plasma Biomarkers in Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P875.	0.4	0
11	Apolipoprotein E isotype-dependent modulation of microRNA-146a in plasma and brain. NeuroReport, 2016, 27, 791-795.	0.6	18
12	Clinical development of curcumin in neurodegenerative disease. Expert Review of Neurotherapeutics, 2015, 15, 629-637.	1.4	144
13	Dietary DHA supplementation in an APP/PS1 transgenic rat model of AD reduces behavioral and AÎ² pathology and modulates AÎ² oligomerization. Neurobiology of Disease, 2015, 82, 552-560.	2.1	48
14	O2-06-03: Release of c-terminal truncated and intact tau from Alzheimer's disease cortical synapses. , 2015, 11, P186-P187.		0
15	Neuroinflammation in Alzheimer's disease. Lancet Neurology, The, 2015, 14, 388-405.	4.9	4,129
16	Parallel age-associated changes in brain and plasma neuronal pentraxin receptor levels in a transgenic APP/PS1 rat model of Alzheimer's disease. Neurobiology of Disease, 2015, 74, 32-40.	2.1	4
17	Loss of MAP Function Leads to Hippocampal Synapse Loss and Deficits in the Morris Water Maze with Aging. Journal of Neuroscience, 2014, 34, 7124-7136.	1.7	120
18	P3-107: RETINAL IMAGING OF AB DEPOSITS IN AD PATIENTS: FROM HISTOLOGICAL EXAMINATION TO CLINICAL TRIALS. , 2014, 10, P667-P667.		1

#	Article	IF	Citations
19	Curcumin Suppresses Soluble Tau Dimers and Corrects Molecular Chaperone, Synaptic, and Behavioral Deficits in Aged Human Tau Transgenic Mice. Journal of Biological Chemistry, 2013, 288, 4056-4065.	1.6	166
20	PAK1 in Alzheimerâ€™s and Huntingtonâ€™s Diseases. , 2013, , 107-124.		0
21	PAK in Alzheimer disease, Huntington disease and X-linked mental retardation. Cellular Logistics, 2012, 2, 117-125.	0.9	73
22	Protection of primary neurons and mouse brain from Alzheimer's pathology by molecular tweezers. Brain, 2012, 135, 3735-3748.	3.7	86
23	Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimer's Research and Therapy, 2012, 4, 43.	3.0	402
24	Improvement of neuropathology and transcriptional deficits in CAG 140 knock-in mice supports a beneficial effect of dietary curcumin in Huntington's disease. Molecular Neurodegeneration, 2012, 7, 12.	4.4	100
25	Lack of efficacy of curcumin on neurodegeneration in the mouse model of Niemannâ€“Pick C1. Pharmacology Biochemistry and Behavior, 2012, 101, 125-131.	1.3	18
26	What was lost in translation in the DHA trial is whom you should intend to treat. Alzheimer's Research and Therapy, 2011, 3, 2.	3.0	19
27	[F-18]FDDNP microPET imaging correlates with brain Aβ burden in a transgenic rat model of Alzheimer disease: Effects of aging, in vivo blockade, and anti-Aβ antibody treatment. Neurobiology of Disease, 2011, 43, 565-575.	2.1	33
28	Why Pleiotropic Interventions are Needed for Alzheimer's Disease. Molecular Neurobiology, 2010, 41, 392-409.	1.9	141
29	Thinking outside the box about COX-1 in Alzheimer's disease. Neurobiology of Disease, 2010, 38, 492-494.	2.1	7
30	Dietary fatty acids and the aging brain. Nutrition Reviews, 2010, 68, S102-S111.	2.6	68
31	DHA May Prevent Age-Related Dementia. Journal of Nutrition, 2010, 140, 869-874.	1.3	112
32	Short-term total sleep deprivation in the rat increases antioxidant responses in multiple brain regions without impairing spontaneous alternation behavior. Behavioural Brain Research, 2010, 207, 305-309.	1.2	58
33	Mechanisms of Action of Non-Steroidal Anti-Inflammatory Drugs for the Prevention of Alzheimers Disease. CNS and Neurological Disorders - Drug Targets, 2010, 9, 140-148.	0.8	70
34	Diet, Abeta Oligomers and Defective Insulin and Neurotrophic Factor Signaling in Alzheimerâ€™s Disease. Research and Perspectives in Alzheimer's Disease, 2010, , 183-199.	0.1	0
35	Reduction of SorLA/LR11, a Sorting Protein Limiting β-Amyloid Production, in Alzheimer Disease Cerebrospinal Fluid. Archives of Neurology, 2009, 66, 448-57.	4.9	79
36	GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals. Neurobiology of Disease, 2009, 33, 193-206.	2.1	149

#	Article	IF	Citations
37	Omega-3 fatty acids and dementia. Prostaglandins Leukotrienes and Essential Fatty Acids, 2009, 81, 213-221.	1.0	193
38	Â-Amyloid Oligomers Induce Phosphorylation of Tau and Inactivation of Insulin Receptor Substrate via c-Jun N-Terminal Kinase Signaling: Suppression by Omega-3 Fatty Acids and Curcumin. Journal of Neuroscience, 2009, 29, 9078-9089.	1.7	474
39	Curcumin Structure-Function, Bioavailability, and Efficacy in Models of Neuroinflammation and Alzheimer's Disease. Journal of Pharmacology and Experimental Therapeutics, 2008, 326, 196-208.	1.3	548
40	p21-activated Kinase-aberrant Activation and Translocation in Alzheimer Disease Pathogenesis. Journal of Biological Chemistry, 2008, 283, 14132-14143.	1.6	109
41	Use of Copper and Insulin-Resistance to Accelerate Cognitive Deficits and Synaptic Protein Loss in a Rat AÎ²-Infusion Alzheimer's Disease Model. Journal of Alzheimer's Disease, 2008, 15, 625-640.	1.2	15
42	Omega-3 Fatty Acid Docosahexaenoic Acid Increases SorLA/LR11, a Sorting Protein with Reduced Expression in Sporadic Alzheimer's Disease (AD): Relevance to AD Prevention. Journal of Neuroscience, 2007, 27, 14299-14307.	1.7	103
43	NEUROPROTECTIVE EFFECTS OF CURCUMIN. , 2007, 595, 197-212.		393
44	Evidence of AÎ²â€•and transgeneâ€dependent defects in ERKâ€CREB signaling in Alzheimerâ€™s models. Journal of Neurochemistry, 2007, 103, 1594-1607.	2.1	105
45	The role of insulin and neurotrophic factor signaling in brain aging and Alzheimerâ€™s Disease. Experimental Gerontology, 2007, 42, 10-21.	1.2	176
46	Commentary on â€œCytoskeletal modulators and pleiotropic strategies for Alzheimer drug discovery.â€• Pleiotropic approaches to Alzheimer's and other diseases of aging. , 2006, 2, 284-286.		4
47	Alzheimer's amyloid story finds its star. Trends in Molecular Medicine, 2006, 12, 395-396.	3.5	17
48	Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nature Neuroscience, 2006, 9, 234-242.	7.1	294
49	Antibodies against Î²-amyloid reduce aÎ² oligomers, glycogen synthase kinase-3Î² activation and Ï„ phosphorylation in vivo and in vitro. Journal of Neuroscience Research, 2006, 83, 374-384.	1.3	126
50	Docosahexaenoic Acid Protects from Amyloid and Dendritic Pathology in an Alzheimer's Disease Mouse Model. Nutrition and Health, 2006, 18, 249-259.	0.6	100
51	beta-Amyloid infusion results in delayed and age-dependent learning deficits without role of inflammation or beta-amyloid deposits. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 8852-8857.	3.3	45
52	Tetrahydrocurcumin in plasma and urine: Quantitation by high performance liquid chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 824, 206-212.	1.2	19
53	Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease. European Journal of Neuroscience, 2005, 22, 617-626.	1.2	234
54	A Potential Role of the Curry Spice Curcumin in Alzheimers Disease. Current Alzheimer Research, 2005, 2, 131-136.	0.7	436

#	Article	IF	Citations
55	Ibuprofen Suppresses Interleukin-1Î² Induction of Pro-Amyloidogenic Î±1-Antichymotrypsin to Ameliorate Î²-Amyloid (AÎ²) Pathology in Alzheimer's Models. Neuropsychopharmacology, 2005, 30, 1111-1120.	2.8	100
56	Curcumin Inhibits Formation of Amyloid Î² Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo. Journal of Biological Chemistry, 2005, 280, 5892-5901.	1.6	2,024
57	Prevention of Alzheimer's disease: Omega-3 fatty acid and phenolic anti-oxidant interventions. Neurobiology of Aging, 2005, 26, 133-136.	1.5	196
58	A Diet Enriched with the Omega-3 Fatty Acid Docosahexaenoic Acid Reduces Amyloid Burden in an Aged Alzheimer Mouse Model. Journal of Neuroscience, 2005, 25, 3032-3040.	1.7	641
59	NSAID and Antioxidant Prevention of Alzheimer's Disease: Lessons from In Vitro and Animal Models. Annals of the New York Academy of Sciences, 2004, 1035, 68-84.	1.8	121
60	Role of LRP in TGF?2-mediated neuronal uptake of A? and effects on memory. Journal of Neuroscience Research, 2004, 77, 217-228.	1.3	23
61	Insulin-Degrading Enzyme as a Downstream Target of Insulin Receptor Signaling Cascade: Implications for Alzheimer's Disease Intervention. Journal of Neuroscience, 2004, 24, 11120-11126.	1.7	290
62	Aminopyridazines inhibit Î²-amyloid-induced glial activation and neuronal damage in vivo. Neurobiology of Aging, 2004, 25, 1283-1292.	1.5	91
63	Docosahexaenoic Acid Protects from Dendritic Pathology in an Alzheimer's Disease Mouse Model. Neuron, 2004, 43, 633-645.	3.8	668
64	Church baptizes Joseph and Perry. Eccentric views absolved. Neurobiology of Aging, 2001, 22, 147-150.	1.5	5
65	The Curry Spice Curcumin Reduces Oxidative Damage and Amyloid Pathology in an Alzheimer Transgenic Mouse. Journal of Neuroscience, 2001, 21, 8370-8377.	1.7	1,374
66	Lipoprotein effects on aÎ² accumulation and degradation by microglia in vitro. Journal of Neuroscience Research, 1999, 57, 504-520.	1.3	44
67	Mapping biochemistry to metabolism. NeuroReport, 1999, 10, 2911-2917.	0.6	49
68	Effect of chloroquine and leupeptin on intracellular accumulation of amyloid-beta (AÎ²) 1-42 peptide in a murine N9 microglial cell line. FEBS Letters, 1998, 436, 439-444.	1.3	29
69	Effects of Transforming Growth Factor-Î² (Isoforms 1â€“3) on Amyloid-Î² Deposition, Inflammation, and Cell Targeting in Organotypic Hippocampal Slice Cultures. Journal of Neuroscience, 1998, 18, 10366-10374.	1.7	56
70	Protease Inhibitor Coinfusion with Amyloid Î²-Protein Results in Enhanced Deposition and Toxicity in Rat Brain. Journal of Neuroscience, 1998, 18, 8311-8321.	1.7	77
71	Spiral Intercellular Calcium Waves in Hippocampal Slice Cultures. Journal of Neurophysiology, 1998, 79, 1045-1052.	0.9	131
72	Rodent models of Alzheimer's disease: Rat aÎ² infusion approaches to amyloid deposits. Neurobiology of Aging, 1996, 17, 311-321.	1.5	132

#	Article	IF	Citations
73	Lack of long-term effects after Î²-amyloid protein injections in rat brain. Neurobiology of Aging, 1994, 15, 601-607.	1.5	68
74	Monoclonal antibody to the C-terminus of Î²-amyloid. NeuroReport, 1994, 5, 2117-2120.	0.6	45
75	Enhanced expression of transforming growth factor Î²1 in the rat brain after a localized cerebral injury. Brain Research, 1992, 587, 216-225.	1.1	221